中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2013年
2期
151-154
,共4页
孙松韦%邹跃%刘家赵%陈星宇%王成%李晓
孫鬆韋%鄒躍%劉傢趙%陳星宇%王成%李曉
손송위%추약%류가조%진성우%왕성%리효
局部晚期胰腺癌%调强放疗%三维适形放疗%剂量学%局部化疗
跼部晚期胰腺癌%調彊放療%三維適形放療%劑量學%跼部化療
국부만기이선암%조강방료%삼유괄형방료%제량학%국부화료
Locally advanced pancreatic cancer%IMRT%3D-CRT%Dosimetry%Regional chemotherapy
目的 比较局部晚期胰腺癌放疗中三维适形放疗(3 D-CRT)与调强放疗(IMRT)技术的剂量学差异,观察IMRT联合吉西他滨局部化疗的临床疗效.方法 选择10例局部晚期胰腺癌患者的CT定位图像,分别设计3D-CRT和IMRT计划,利用剂量体积直方图(DVH)评价2种治疗计划的剂量.回顾性收集2008年5月至2010年5月符合入组标准的25例接受IMRT联合吉西他滨局部介入治疗的局部晚期胰腺癌患者(联合治疗组),选择同时期入院的仅接受吉西他滨局部介入治疗的25例晚期胰腺癌患者(单化组)做对比研究,比较2组的临床疗效及不良反应.结果 IMRT计划中十二指肠、肝脏、胃、双肾、小肠的平均剂量及高剂量区照射体积明显低于3D-CRT计划.联合治疗组与单化组1、2年生存率分别为60%、28%和36%、12%,中位生存期分别为15个月和10个月(x2 =4.16,P<0.05),有效率分别为64%和32%(x2 =5.13,P<0.05).联合治疗组上消化道反应发生率高于单化组(Z=-2.35,P<0.05),而骨髓抑制、肝肾功能损害情况差异无统计学意义.结论 与三维适形放疗相比,调强放疗在保证靶区高剂量的情况下降低危及器官的剂量,联合吉西他滨局部化疗可显著提高局部晚期胰腺癌患者的生存率,延长的中位生存时间,且不良反应轻微.
目的 比較跼部晚期胰腺癌放療中三維適形放療(3 D-CRT)與調彊放療(IMRT)技術的劑量學差異,觀察IMRT聯閤吉西他濱跼部化療的臨床療效.方法 選擇10例跼部晚期胰腺癌患者的CT定位圖像,分彆設計3D-CRT和IMRT計劃,利用劑量體積直方圖(DVH)評價2種治療計劃的劑量.迴顧性收集2008年5月至2010年5月符閤入組標準的25例接受IMRT聯閤吉西他濱跼部介入治療的跼部晚期胰腺癌患者(聯閤治療組),選擇同時期入院的僅接受吉西他濱跼部介入治療的25例晚期胰腺癌患者(單化組)做對比研究,比較2組的臨床療效及不良反應.結果 IMRT計劃中十二指腸、肝髒、胃、雙腎、小腸的平均劑量及高劑量區照射體積明顯低于3D-CRT計劃.聯閤治療組與單化組1、2年生存率分彆為60%、28%和36%、12%,中位生存期分彆為15箇月和10箇月(x2 =4.16,P<0.05),有效率分彆為64%和32%(x2 =5.13,P<0.05).聯閤治療組上消化道反應髮生率高于單化組(Z=-2.35,P<0.05),而骨髓抑製、肝腎功能損害情況差異無統計學意義.結論 與三維適形放療相比,調彊放療在保證靶區高劑量的情況下降低危及器官的劑量,聯閤吉西他濱跼部化療可顯著提高跼部晚期胰腺癌患者的生存率,延長的中位生存時間,且不良反應輕微.
목적 비교국부만기이선암방료중삼유괄형방료(3 D-CRT)여조강방료(IMRT)기술적제량학차이,관찰IMRT연합길서타빈국부화료적림상료효.방법 선택10례국부만기이선암환자적CT정위도상,분별설계3D-CRT화IMRT계화,이용제량체적직방도(DVH)평개2충치료계화적제량.회고성수집2008년5월지2010년5월부합입조표준적25례접수IMRT연합길서타빈국부개입치료적국부만기이선암환자(연합치료조),선택동시기입원적부접수길서타빈국부개입치료적25례만기이선암환자(단화조)주대비연구,비교2조적림상료효급불량반응.결과 IMRT계화중십이지장、간장、위、쌍신、소장적평균제량급고제량구조사체적명현저우3D-CRT계화.연합치료조여단화조1、2년생존솔분별위60%、28%화36%、12%,중위생존기분별위15개월화10개월(x2 =4.16,P<0.05),유효솔분별위64%화32%(x2 =5.13,P<0.05).연합치료조상소화도반응발생솔고우단화조(Z=-2.35,P<0.05),이골수억제、간신공능손해정황차이무통계학의의.결론 여삼유괄형방료상비,조강방료재보증파구고제량적정황하강저위급기관적제량,연합길서타빈국부화료가현저제고국부만기이선암환자적생존솔,연장적중위생존시간,차불량반응경미.
Objective To compare the dose distribution between three-dimensional conformal radiotherapy(3D-CRT) and intensity-modulated radiotherapy (IMRT) in treating locally advanced pancreatic cancer,and report the efficacy of IMRT combined with regional chemotherapy using gemcitabine (GEM).Methods Ten patients with locally advanced pancreatic cancer were enrolled in this study.3D-CRT and IMRT plans were designed for each patient.The dose distributions of target volume and normal tissues were analyzed using the dose volume histogram (DVH).Twenty-five locally advanced pancreatic cancers patients who were treated by IMRT combined with regional chemotherapy using gemcitabine (combined group) were retrospective analyzed,as well as 25 hospitalized patients of the same period who were treated by regional chemotherapy using gemcitabine alone (chemotherapy alone group).The therapeutic efficacy and adverse events were compared between two groups.Results IMRT plans decrease the mean dose and volume of duodenum,liver,stomach,both kidney and small bowel that received highdose irradiation.The 1-,2-year survival rate of the combined group and chemotherapy alone group was 60%,28% and 36%,12%.The median survival time of two groups was 15 and 10 months,respectively (x2 =4.16,P <0.05).The total response rate of the combined group and the chemotherapy alone group was 64% and 32%,respectively (x2 =5.13,P < 0.05).The upper gastrointestinal side-effect rate of the combined group was higher than that of the chemotherapy alone group(Z =-2.354,P < 0.05).There was no statistic significance in hematologic toxicity,liver and renal functional damage between the two groups.Conclusions Compared with 3D-CRT plan,IMRT plan could reduce the dose of organ at risks.IMRT combined with regional chemotherapy using gemcitabine could significantly improve the survival rate of patients with locally advanced pancreatic cancer with mild adverse events.